It seems that a novel therapeutic scheme of CQ-sensitizing pancreatic cancer cells to TH301-driven death opens a new window for the simultaneous modulation of autophagy and circadian clock functionalities in the clinical management of the disease. This evidence concerns the gene CLOCK and familial pancreatic carcinoma.